Previous close | 2.5000 |
Open | 2.5000 |
Bid | 0.0000 |
Ask | 0.0000 |
Strike | 160.00 |
Expiry date | 2024-11-15 |
Day's range | 2.5000 - 2.5000 |
Contract range | N/A |
Volume | |
Open interest | N/A |
A blood test could help reduce costs for health plans by reliably identifying patients who might be able to safely forgo chemotherapy after surgery for stage II colorectal cancer, according to a study published today in JAMA Health Forum, a member of the JAMA Network. Researchers from Haystack Oncology, a Quest Diagnostics (NYSE: DGX) company and developer of the Haystack MRD™ tumor-informed ctDNA MRD technology, City of Hope and the Walter and Eliza Hall Institute of Medical Research conducted
Amedisys (AMED) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Quest Diagnostics (DGX) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.